Ghrelin modulates baroreflex-regulation of sympathetic vasomotor tone in healthy humans

What Was Tested

Researchers studied Ghrelin in this randomized controlled trial publication.

Ghrelin, a neuropeptide originally known for its growth hormone-releasing and orexigenic properties, exerts important pleiotropic effects on the cardiovascular system.

The present study aimed at elucidating the acute effect of ghrelin on sympathetic outflow to the muscle vascular bed (muscle sympathetic nerve activity, MSNA) and on baroreflex-mediated arterial blood pressure (BP) regulation in healthy humans.

Who Took Part

The abstract describes 12 men taking part.

PubMed indexes the participants as young adults and adults, men only.

How the Study Was Run

The design is described as randomized, double-blind, placebo-controlled and crossover.

The men were allocated by chance, so the Ghrelin group and the comparison group should start out alike.

Blinding on both sides kept the men and researchers unaware of who received Ghrelin.

Some men received a placebo instead of Ghrelin, giving a reference point.

Each person switched between Ghrelin and the comparison at some point, usually with a gap in between.

What Was Measured

Sensitivity of arterial baroreflex was repeatedly tested by injection of vasoactive substances based on the modified Oxford protocol.

The subject headings attached to it are Baroreflex, Blood Pressure, Ghrelin, Heart Rate, Sympathetic Nervous System and Vasomotor System.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Ghrelin in 12 men.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The publication is from 2012 (American journal of physiology. Regulatory, integrative and comparative physiology), a journal based in United States.

More context: the Ghrelin compound page, all human trials.